Details: pack, label wording, sources, registration
Omeprazole Neo 20 mg, Capsule
capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Oral omeprazole for clinically justified acid suppression in suspected or documented gastroduodenal ulceration/erosion or reflux oesophagitis; not routine treatment of uncomplicated vomiting, gastritis, pancreatitis, hepatic or renal disease
6.8/10
Situational / acceptable
Details →
vetman assessment
Omeprazole Neo
×
20 mg, capsule, human medicine
Assessed clinical scope Dog · Oral omeprazole for clinically justified acid suppression in suspected or documented gastroduodenal ulceration/erosion or reflux oesophagitis; not routine treatment of uncomplicated vomiting, gastritis, pancreatitis, hepatic or renal disease · By mouth
Care setting Veterinary-directed inpatient or outpatient treatment, normally given before food on a consistent twice-daily schedule for active acid-related disease, with diagnosis and duration reassessed
vetman score
6.8/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-035925 · Verified on 16 Oct 2026
Off-label use
A clinically credible acid suppressant for selected ulcerative or reflux disease, but not routine nonspecific gastroprotection. The whole 20 mg human capsule is workable only when it matches the dog's calculated dose; smaller patients need a more suitable formulation.
Regulatory and scientific credibility 6.5/10
The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.
Clinical efficacy 7.5/10
Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.
Safety and tolerability 7.0/10
Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.
Clinical practicality 5.5/10
This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use omeprazole as automatic cover for uncomplicated vomiting, gastritis, pancreatitis, hepatic disease, renal disease, corticosteroids or NSAIDs without an individual ulceration/bleeding rationale. Diagnose and treat the underlying cause. Do not use after a previous hypersensitivity reaction to omeprazole, another substituted benzimidazole or an excipient. Stop and treat urgently for facial swelling, bronchospasm, collapse or anaphylaxis. Alarm signs such as weight loss, recurrent vomiting, dysphagia, haematemesis, melaena or anaemia require investigation. Acid suppression can mask signs and delay diagnosis of neoplasia, foreign material or another bleeding lesion. Severe hepatic dysfunction can increase systemic exposure. Review liver disease, clinical response and adverse effects and use the lowest justified effective regimen. Review concurrent medicines: CYP2C19 effects can alter clopidogrel, diazepam, phenytoin, warfarin or tacrolimus exposure, while raised gastric pH can reduce absorption of itraconazole/ketoconazole, mycophenolate, iron and other pH-dependent drugs. Reassess prolonged treatment. Sustained acid suppression can cause hypergastrinaemia, altered gastrointestinal flora or infection risk and impaired magnesium/cobalamin/iron handling; monitor according to duration and patient risk. After more than 3-4 weeks of treatment, do not stop abruptly unless safety requires it. Taper a clinically unnecessary PPI to reduce rebound acid hypersecretion and recurrence of acid-related signs. This delayed-release capsule is recorded as whole-only. Do not crush or chew it, and do not treat an unmeasured fraction of enteric-coated beads as an accurate veterinary dose; select a suitable lower strength or validated compounded form. Assessment sources +
Close
Cat
Oral omeprazole for clinically justified acid suppression in suspected or documented gastroduodenal ulceration/erosion or reflux oesophagitis; not routine treatment of uncomplicated vomiting, gastritis, pancreatitis, hepatic or renal disease
5.5/10
Weak evidence support
Details →
vetman assessment
Omeprazole Neo
×
20 mg, capsule, human medicine
Assessed clinical scope Cat · Oral omeprazole for clinically justified acid suppression in suspected or documented gastroduodenal ulceration/erosion or reflux oesophagitis; not routine treatment of uncomplicated vomiting, gastritis, pancreatitis, hepatic or renal disease · By mouth
Care setting Veterinary-directed inpatient or outpatient treatment, normally given before food on a consistent twice-daily schedule for active acid-related disease, with diagnosis and duration reassessed
vetman score
5.5/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-035925 · Verified on 16 Oct 2026
Off-label use
Omeprazole can suppress feline gastric acid, but this exact whole-only 20 mg human capsule cannot deliver the studied approximately 4-6 mg feline dose accurately. The low score reflects the presentation, not rejection of omeprazole in an appropriate feline indication.
Regulatory and scientific credibility 6.5/10
The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.
Clinical efficacy 6.5/10
Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.
Safety and tolerability 6.5/10
Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.
Clinical practicality 0.5/10
The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use omeprazole as automatic cover for uncomplicated vomiting, gastritis, pancreatitis, hepatic disease, renal disease, corticosteroids or NSAIDs without an individual ulceration/bleeding rationale. Diagnose and treat the underlying cause. Do not use after a previous hypersensitivity reaction to omeprazole, another substituted benzimidazole or an excipient. Stop and treat urgently for facial swelling, bronchospasm, collapse or anaphylaxis. Alarm signs such as weight loss, recurrent vomiting, dysphagia, haematemesis, melaena or anaemia require investigation. Acid suppression can mask signs and delay diagnosis of neoplasia, foreign material or another bleeding lesion. Severe hepatic dysfunction can increase systemic exposure. Review liver disease, clinical response and adverse effects and use the lowest justified effective regimen. Review concurrent medicines: CYP2C19 effects can alter clopidogrel, diazepam, phenytoin, warfarin or tacrolimus exposure, while raised gastric pH can reduce absorption of itraconazole/ketoconazole, mycophenolate, iron and other pH-dependent drugs. Reassess prolonged treatment. Sustained acid suppression can cause hypergastrinaemia, altered gastrointestinal flora or infection risk and impaired magnesium/cobalamin/iron handling; monitor according to duration and patient risk. After more than 3-4 weeks of treatment, do not stop abruptly unless safety requires it. Taper a clinically unnecessary PPI to reduce rebound acid hypersecretion and recurrence of acid-related signs. This delayed-release capsule is recorded as whole-only. Do not crush or chew it, and do not treat an unmeasured fraction of enteric-coated beads as an accurate veterinary dose; select a suitable lower strength or validated compounded form. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, human
In force until 21 Jul 2027
Human (Ministry of Health, RAMA)
In the register: ომეპრაზოლი ნეო 20 მგ, კაფსულა
№ რ-035925
Verified on: 16 Oct 2026
EU
Yes, human
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
